OKYO Pharma Ltd ADR (OKYO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OKYO Pharma Ltd ADR (OKYO) has a cash flow conversion efficiency ratio of -0.357x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.41 Million) by net assets ($12.34 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of OKYO Pharma Ltd ADR for the company's overall valuation and market capitalisation.
OKYO Pharma Ltd ADR - Cash Flow Conversion Efficiency Trend (2008–2026)
This chart illustrates how OKYO Pharma Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OKYO Pharma Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OKYO Pharma Ltd ADR ranked by their cash flow conversion efficiency. Explore OKYO Pharma Ltd ADR cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sahamit Machinery Public Company Limited
BK:SMIT
|
0.023x |
|
MGI Digital
PA:ALMDG
|
0.015x |
|
Cactus Acquisition Corp 1 Ltd
NASDAQ:CCTS
|
-0.033x |
|
Solidion Technology Inc.
NASDAQ:STI
|
-0.183x |
|
Ginar Technology Co Ltd
TWO:6151
|
0.074x |
|
Sentry Select Primary Metals Corp
TO:PME
|
0.010x |
|
Heron Therapeuti
NASDAQ:HRTX
|
-0.169x |
|
Ahoku Electronic Co
TW:3002
|
-0.016x |
Annual Cash Flow Conversion Efficiency for OKYO Pharma Ltd ADR (2008–2026)
The table below shows the annual cash flow conversion efficiency of OKYO Pharma Ltd ADR from 2008 to 2026. View OKYO live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $12.34 Million | $-5.94 Million | -0.481x | -247.47% |
| 2025-03-31 | $-5.55 Million | $-1.81 Million | 0.326x | -79.78% |
| 2024-03-31 | $-5.88 Million | $-9.49 Million | 1.614x | -56.93% |
| 2023-03-31 | $-2.05 Million | $-7.70 Million | 3.748x | +302.02% |
| 2022-03-31 | $2.95 Million | $-5.47 Million | -1.855x | -516.71% |
| 2021-03-31 | $5.32 Million | $-1.60 Million | -0.301x | -103.50% |
| 2020-03-31 | $-139.80K | $-1.20 Million | 8.599x | +243.95% |
| 2019-03-31 | $333.14K | $-1.99 Million | -5.973x | -617.91% |
| 2018-03-31 | $1.92 Million | $-1.59 Million | -0.832x | -3413.06% |
| 2017-03-31 | $27.50 Million | $-651.27K | -0.024x | -16.45% |
| 2016-03-31 | $32.00 Million | $-650.88K | -0.020x | +51.37% |
| 2015-03-31 | $33.90 Million | $-1.42 Million | -0.042x | +43.12% |
| 2014-03-31 | $46.96 Million | $-3.45 Million | -0.074x | +13.40% |
| 2013-03-31 | $45.02 Million | $-3.82 Million | -0.085x | +24.82% |
| 2012-03-31 | $41.36 Million | $-4.67 Million | -0.113x | -38.07% |
| 2011-03-31 | $16.01 Million | $-1.31 Million | -0.082x | -403.21% |
| 2010-03-31 | $54.05 Million | $-878.61K | -0.016x | -174.19% |
| 2009-03-31 | $38.18 Million | $-226.35K | -0.006x | +68.33% |
| 2008-03-31 | $27.46 Million | $-513.95K | -0.019x | -- |
About OKYO Pharma Ltd ADR
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to t… Read more